Corpus ID: 34978924

[Clinical trial of oxyprothepin decanoate (author's transl)].

  title={[Clinical trial of oxyprothepin decanoate (author's transl)].},
  author={J. Kabe{\vs} and R. Balon and L. Hanzl{\'i}cek and M. Skovajsov{\'a} and H. Kozakova},
  journal={Ceskoslovenska psychiatrie},
  volume={76 1},
2 Citations

Topics from this paper

Fluphenazine decanoate (depot) and enanthate for schizophrenia.
Overall, the quality of the evidence is low to very low, and use of fluphenazine decanoate does not result in any significant differences in death, nor does it reduce relapse over six months to one year, but one longer-term study found that relapse was significantly reduced in the fl uphenazine arm. Expand
Depot perphenazine decanoate and enanthate for schizophrenia.
Perphenazine enanthate was not significantly any better or worse than other depot antipsychotics in most of the main outcomes such as global state, relapse or leaving the study early, and clinicians will be in doubt as to the effects of perphenazine depots. Expand